News and Events

June 13, 2018
Immunomedics announces pricing of public offering of common stock
June 11, 2018
Immunomedics announces proposed public offering of common stock
June 04, 2018
Immunomedics provides business update at the ASCO 2018 investor event
June 03, 2018
Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers
Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer
June 01, 2018
Immunomedics announces pivotal study of sacituzumab govitecan in patients with locally advanced or metastatic urothelial cancer
May 30, 2018
Immunomedics to present at Jefferies 2018 Global Healthcare Conference
May 21, 2018
Immunomedics submits biologics license application for sacituzumab govitecan to the U.S. Food and Drug Administration
May 09, 2018
Immunomedics announces third quarter fiscal 2018 results and provides corporate update
May 02, 2018
Immunomedics to report third quarter fiscal 2018 results and host conference call and webcast
April 25, 2018
Immunomedics announces oral presentation of sacituzumab govitecan in hormone receptor-positive (HR+) metastatic breast cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) annual meeting
April 09, 2018
Immunomedics appoints Dr. Robert Iannone head of Research & Development and Chief Medical Officer
March 05, 2018
Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference
February 15, 2018
Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference
February 08, 2018
Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update
February 06, 2018
Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018
January 11, 2018
Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer
January 08, 2018
Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million
January 04, 2018
Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference